On Wednesday , Mr. Price , who as health secretary would oversee the Food and Drug Administration , filed papers with the federal government saying he would divest himself of interests he several health care companies , including Innate .Phillip J. Blando , a spokesman for the presidential transition , said that Mr. Price took " his obligation to Mr. Price the public trust very seriously , " and that the Office of Government Ethics had completed an " exhaustive " review of his financial holdingsMr. Price Representatives of Mr. Price and Mr. Collins say they have not Representatives of Mr. Price and Mr. Collins any rules , but what has puzzled Washington and industry insiders alike is how a    Australian biotech , with only one experimental multiple sclerosis drug under development , attracted a coterie of Washington investors , Washington the man who Chris Chris is just a cheerleader for the company and Tom Price jumped in head over heels , " said Craig Holman , the government affairs lobbyist for Public Citizen , a consumer group , which has asked for an investigation by the Securities and Exchange Commission ."